Search Results 241-250 of 17296 for Cyclophosphamide

1. Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy - Mayo Clinic

   ... cyclophosphamide [AC]). Cisplatin at a dose of ≥70mg/m^2, with or without other chemotherapy agent(s) OR; Anthracycline (60 mg/m^2) plus cyclophosphamide(600 ...

2. Diagnosed with focal segmental glomerulosclerosis (FSGS)? Here's what to know about your treatment options - Mayo Clinic

   ... cyclophosphamide (Cytoxan) or adrenocorticotropic hormone (ACTH), among others. As always, talk with your care team about your options, including ...

3. Biological Therapy For Cancer Clinical Trials - Mayo Clinic Research

   ... cyclophosphamide, doxorubicin, vincristine and prednisone/prednisolone [R-CHOP]) is effective and safe, compared with placebo in combination with standard ...

4. Pemphigus - Diagnosis and treatment - Mayo Clinic

   Examples are azathioprine (Imuran, Azasan), mycophenolate (Cellcept) and cyclophosphamide. These too can have severe side effects, including an increased ...

5. Lifileucel (intravenous route) - Side effects & uses - Mayo Clinic

   It is given after completing treatment with other cancer medicines (eg, fludarabine, cyclophosphamide). This medicine usually comes with a patient ...

6. Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis - Mayo Clinic

   Treatment with >1 IV dose of cyclophosphamide and/or >14 days of oral cyclophosphamide ... cyclophosphamide, glucocorticoids, or plasma exchange or absolutely ...

7. T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer - Mayo Clinic

   ... cyclophosphamide-docetaxel/trastuzumab/pertuzumab (FAC-TH(P)), or fluorouracil/epirubicin/cyclophosphamide-docetaxel/trastuzumab/pertuzumab (FEC-TH(P)).

8. CardiovascularUpdate

   Type 1 chemotherapy- related left ventricular (lV) systolic dysfunc- tion is caused by agents such as doxorubicin, epirubicin, idarubicin, cyclophosphamide, and.

9. Ide-cel, a BCMA-directed CAR-T cell therapy, shows favorable risk-benefit profile and response - Mayo Clinic

   Treatment schema included lymphodepletion chemotherapy with fludarabine and cyclophosphamide on days -5, -4 and -3, and ide-cel infusion on day 0. "What was ...

10. Bone Cancer Clinical Trials - Mayo Clinic Research

    Drugs used in chemotherapy, such as vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, ifosfamide, and etoposide, work in different ways to stop ...